970*90
768
468
mobile

​Allergen acquires Cipla (EU) Ltd's 16.7 percent stake

Franchise India Bureau
Franchise India Bureau Sep 29 2017 - 1 min read
​Allergen acquires Cipla (EU) Ltd's 16.7 percent stake
Chase was recently financed by a Series B consortium consisting of New Rhein Healthcare, Edmond de Rothschild Investment Partners and Cipla UK.

Cipla, one of the top pharmaceutical companies in India has said in a statement that Chase Pharamceuticals Corporation, a Delaware-based company, in which Cipla (EU) Ltd, its UK arm has 16.7 percent stake has been acquired by Allergen plc, an Ireland-headquartered company.

Cipla said, "Allergan has agreed to pay USD 125 million upfront plus potential regulatory and commercial milestones of up to USD 875 million to the shareholders of Chase."

The company said that Cipla UK had acquired a minority stake in Chase in May 2014 via a syndicated venture investment.

Chandru Chawla, Head of Corporate Strategy and Cipla New Ventures, said: "We believe that Chase's pipeline will be successful at Allergan, given their strength as a leading CNS commercial franchise."

David Nicholson, Chief Research and Development Officer, Allergan, said, "This acquisition adds a new Phase 3 ready programme for Alzheimer's disease to our CNS portfolio and builds on our commitment to develop innovative approaches to improve the lives of millions of patients suffering from this devastating illness."

Chase was recently financed by a Series B consortium consisting of New Rhein Healthcare, Edmond de Rothschild Investment Partners and Cipla UK.

Subscribe Newsletter
Submit your email address to receive the latest updates on news & host of opportunities
Entrepreneur Magazine

For hassle free instant subscription, just give your number and email id and our customer care agent will get in touch with you

or Click here to Subscribe Online

Newsletter Signup

Share your email address to get latest update from the industry